WUXI BIO (02269) has announced a positive profit alert. The company expects its total revenue for the full year ending December 31, 2025, to increase by approximately 16.7% to RMB 21.79 billion compared to the same period last year. The gross profit margin is projected to improve by about 5 percentage points to 46.0%. Adjusted gross profit is anticipated to grow to approximately RMB 10.638 billion, representing a year-on-year increase of about 25.5%. Profit for the full year ending December 31, 2025, and profit attributable to the company's equity shareholders are expected to increase by approximately 45.3% to RMB 5.733 billion and about 46.3% to RMB 4.908 billion, respectively. Furthermore, after adjusting for share-based compensation expenses, foreign exchange gains and losses, equity investment gains or losses, gains or losses from asset disposals and restructuring, and related one-off costs, the company's non-IFRS adjusted net profit is forecast to grow by about 22.0% to RMB 6.586 billion. This growth is primarily attributed to the following factors: (i) the successful execution of the "Follow and Win the Molecule" strategy, coupled with leading technology platforms, industry-leading project delivery times, and an excellent track record of project execution, which have driven revenue growth; (ii) the expansion of the service portfolio for the biopharmaceutical industry, including research and discovery services, pre-IND development services, and clinical and commercial manufacturing services, based on rapidly developing technology platforms such as bispecific antibodies and ADCs (Antibody-Drug Conjugates); (iii) increased revenue from research services generated by the company's multiple advanced technologies; (iv) improved utilization of existing and newly added capacity, including the ramp-up of production capacity at European manufacturing sites; (v) cost savings and efficiency improvements achieved through the Wuxi Biologics Lean Operation Management System (WBS) and digital solutions; and (vi) investment income gained from the company's investment portfolio.